Posts

Featured Post

Discover Moscow in Arabic offers GCC travelers an integrated, accessible and information-rich platform to fully plan their visit to the Russian capital

-
Image
    In response to growing demand from travelers from the GCC and the wider Arab region, the Moscow City Tourism Committee, the sectoral executive body responsible for implementing, developing and regulating Moscow City's tourism and hospitality policy, has launched the Arabic-language version of Discover Moscow, the city's official tourism information ecosystem . The Arabic version of the website, https://discover.moscow/ar, brings together under one integrated umbrella all travel information, curated recommendations, seasonal ideas and useful tips for visitors planning to visit Moscow. The user-friendly platform, accessible across all devices, helps travelers explore the city’s key attractions, cultural routes, parks, events, restaurants, shopping areas and family-friendly experiences, making it easier to organize a visit before arrival . According to the Moscow City Tourism Committee, this initiative aims at creating a more convenient, meticulous comfortable, and pe...
للمزيد »

TikTok x Blossom AI Hackathon Brings Together Saudi Arabia's Emerging Entrepreneurs and Innovators

-
Image
    TikTok and Blossom Accelerator successfully hosted an AI hackathon that brought together together aspiring entrepreneurs, students, researchers, developers, and AI enthusiasts from across Saudi Arabia for an intensive innovation challenge focused on developing artificial intelligence-driven solutions to real-world challenges.   The initiative reflects a shared commitment to fostering innovation, entrepreneurship, and digital skills development while supporting Saudi Arabia’s rapidly growing AI ecosystem.   The hackathon attracted 63 projects, with participants collaborating in teams to develop AI-powered solutions and innovative concepts with the potential to address real-world opportunities and challenges across a range of sectors. A panel of industry experts evaluated the projects based on innovation, technical execution, scalability, and potential real-world impact. The full-day hackathon was designed to transform promising ideas into testable prototypes...
للمزيد »

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026

-
Image
 Three million prescriptions for Wegovy® pill since launch on January 5th serve as another milestone in one of the strongest US pharmaceutical launches by volume on record1  The majority of new Wegovy® pill prescriptions are for people new to GLP-1 therapy, bringing obesity medicine to many previously untreated1  This news comes as Novo Nordisk has a large presence at the American Diabetes Association’s 2026 Scientific Sessions, including a variety of Wegovy® analyses in adults with obesity    Novo Nordisk today announced Wegovy® (semaglutide) tablets 25 mg have surpassed three million prescriptions in just over five months, establishing Wegovy® pill as one of the strongest US pharmaceutical launches by volume on record.¹ The three million milestone corresponds to one prescription filled roughly every five seconds, reflecting continued uptake since Wegovy® pill became available in January 2026. Further underscoring its rapid adoption, Wegovy® pill reached its in...
للمزيد »

Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

-
Image
    The Novo Nordisk study POSEIDON – including 18,904 patients across 18 countries - showed that cardiovascular (CV) inflammation remains highly prevalent among people with cardiovascular disease (CVD), despite current standard of care treatment1,2   In fact, two in five people with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD), or heart failure, have CV inflammation1,2   This matters because CV inflammation is an independent risk factor for CV events, such as heart attack and stroke, in people living with CVD. In line with ESC guidelines & ACC scientific statement, this calls for action on the importance of measuring hsCRP in CVD patients3, 13, 14, 15   Novo Nordisk today presented new results from the landmark POSEIDON real-world evidence study at the 94th European Atherosclerosis Society (EAS) Congress in Athens, Greece. The study showed that CV inflammation remains highly prevalent among people with CVD ...
للمزيد »